127 related articles for article (PubMed ID: 34864807)
21. Leukemia derived dendritic cell (DC
Pepeldjiyska E; Li L; Gao J; Seidel CL; Blasi C; Özkaya E; Schmohl J; Kraemer D; Schmid C; Rank A; Schmetzer HM
Immunobiology; 2022 Jul; 227(4):152237. PubMed ID: 35749805
[TBL] [Abstract][Full Text] [Related]
22. Volatile Phases Derived from Serum, DC, or MLC Culture Supernatants to Deduce a VOC-Based Diagnostic Profiling Strategy for Leukemic Diseases.
Baudrexler T; Boeselt T; Li L; Bohlscheid S; Boas U; Schmid C; Rank A; Schmohl J; Koczulla R; Schmetzer HM
Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371569
[TBL] [Abstract][Full Text] [Related]
23. Cytokine-driven differentiation of blasts from patients with acute myelogenous and lymphoblastic leukemia into dendritic cells.
Köhler T; Plettig R; Wetzstein W; Schmitz M; Ritter M; Mohr B; Schaekel U; Ehninger G; Bornhäuser M
Stem Cells; 2000; 18(2):139-47. PubMed ID: 10742386
[TBL] [Abstract][Full Text] [Related]
24. Improved effector function of leukemia-specific T-lymphocyte clones trained with AML-derived dendritic cells.
Schuster FR; Buhmann R; Reuther S; Hubner B; Grabrucker C; Liepert A; Reibke R; Lichtner P; Yang T; Kroell T; Kolb HJ; Borkhardt A; Schmetzer H
Cancer Genomics Proteomics; 2008; 5(5):275-86. PubMed ID: 19129558
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of circulating tumor DNA status post-allogeneic hematopoietic stem cell transplantation in AML and MDS.
Nakamura S; Yokoyama K; Shimizu E; Yusa N; Kondoh K; Ogawa M; Takei T; Kobayashi A; Ito M; Isobe M; Konuma T; Kato S; Kasajima R; Wada Y; Nagamura-Inoue T; Yamaguchi R; Takahashi S; Imoto S; Miyano S; Tojo A
Blood; 2019 Jun; 133(25):2682-2695. PubMed ID: 30936070
[TBL] [Abstract][Full Text] [Related]
26. T-cell receptor excision circle levels after allogeneic stem cell transplantation are predictive of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome.
Uzunel M; Sairafi D; Remberger M; Mattsson J; Uhlin M
Stem Cells Dev; 2014 Jul; 23(14):1559-67. PubMed ID: 24617310
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant.
Motabi IH; Ghobadi A; Liu J; Schroeder M; Abboud CN; Cashen AF; Stockler-Goldstein KE; Uy GL; Vij R; Westervelt P; DiPersio JF
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1324-1329. PubMed ID: 27026249
[TBL] [Abstract][Full Text] [Related]
28. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
Kebriaei P; Kline J; Stock W; Kasza K; Le Beau MM; Larson RA; van Besien K
Bone Marrow Transplant; 2005 May; 35(10):965-70. PubMed ID: 15806131
[TBL] [Abstract][Full Text] [Related]
29. Moderate to Severe Marrow Fibrosis As a More Advanced Risk Factor for MDS and MDS-AML Patients With Excess of Blasts Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
Wang J; Wang Q; Zhang H; He Y; Huang Y; Zhang R; Wei J; Ma Q; Pang A; Yang D; Chen X; Jiang E; Feng S; Zhai W; Han M
Transplant Cell Ther; 2021 Aug; 27(8):666.e1-666.e9. PubMed ID: 34020086
[TBL] [Abstract][Full Text] [Related]
30. Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome.
Kong J; Gao MG; Qin YZ; Wang Y; Yan CH; Sun YQ; Chang YJ; Xu LP; Zhang XH; Liu KY; Huang XJ; Zhao XS
BMC Cancer; 2022 Jan; 22(1):11. PubMed ID: 34979982
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
32. One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant.
Bewersdorf JP; Stahl M; Zeidan AM
Expert Rev Hematol; 2019 Aug; 12(8):575-578. PubMed ID: 31225770
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Limitations of Donor T Cell Chimerism after Myeloablative Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Wong E; Mason K; Collins J; Hockridge B; Boyd J; Gorelik A; Szer J; Ritchie DS
Biol Blood Marrow Transplant; 2017 May; 23(5):840-844. PubMed ID: 28167152
[TBL] [Abstract][Full Text] [Related]
34. Antileukemic T-cell responses can be predicted by the composition of specific regulatory T-cell subpopulations.
Schick J; Vogt V; Zerwes M; Kroell T; Kraemer D; Köhne CH; Hausmann A; Buhmann R; Tischer J; Schmetzer H
J Immunother; 2013 May; 36(4):223-37. PubMed ID: 23603857
[TBL] [Abstract][Full Text] [Related]
35. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Schroeder T; Rautenberg C; Krüger W; Platzbecker U; Bug G; Steinmann J; Klein S; Hopfer O; Nachtkamp K; Kondakci M; Geyh S; Haas R; Germing U; Bornhäuser M; Kobbe G
Ann Hematol; 2018 Feb; 97(2):335-342. PubMed ID: 29151133
[TBL] [Abstract][Full Text] [Related]
36. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Lee HC; Saliba RM; Rondon G; Chen J; Charafeddine Y; Medeiros LJ; Alatrash G; Andersson BS; Popat U; Kebriaei P; Ciurea S; Oran B; Shpall E; Champlin R
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1948-54. PubMed ID: 26183077
[TBL] [Abstract][Full Text] [Related]
37. Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group.
Schroeder T; Rachlis E; Bug G; Stelljes M; Klein S; Steckel NK; Wolf D; Ringhoffer M; Czibere A; Nachtkamp K; Dienst A; Kondakci M; Stadler M; Platzbecker U; Uharek L; Luft T; Fenk R; Germing U; Bornhäuser M; Kröger N; Beelen DW; Haas R; Kobbe G
Biol Blood Marrow Transplant; 2015 Apr; 21(4):653-60. PubMed ID: 25540937
[TBL] [Abstract][Full Text] [Related]
38. Paramunity-inducing Factors (PINDs) in dendritic cell (DC) cultures lead to impaired antileukemic functionality of DC-stimulated T-cells.
Ansprenger C; Vogt V; Schick J; Hirn-Lopez A; Vokac Y; Harabacz I; Braeu M; Kroell T; Karenberg A; Kolb HJ; Schmetzer H
Cell Immunol; 2018 Jun; 328():33-48. PubMed ID: 29580554
[TBL] [Abstract][Full Text] [Related]
39.
Shallis RM; Podoltsev NA; Gowda L; Zeidan AM; Gore SD
Expert Rev Hematol; 2020 May; 13(5):447-460. PubMed ID: 32182435
[No Abstract] [Full Text] [Related]
40. Diagnostic criteria for hypocellular acute leukemia: a clinical entity distinct from overt acute leukemia and myelodysplastic syndrome.
Nagai K; Kohno T; Chen YX; Tsushima H; Mori H; Nakamura H; Jinnai I; Matsuo T; Kuriyama K; Tomonaga M; Bennett JM
Leuk Res; 1996 Jul; 20(7):563-74. PubMed ID: 8795690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
